Nevirapine’s (NVP) pharmaceutical manufacturer recommended the avoidance of NVP in females and males with baseline CD4 counts >250 and >400, respectively. This safety measure was challenged by research results that showed similar proportions of adverse events in high and low baseline CD4 count patients. WHO’s antiretroviral therapy guidelines recommended the use of NVP in patients with CD4 counts < 350. Whether this recommendation would result in increase of NVP-related adverse reaction reports in Namibia was not known. Consequently, the pharmacovigilance centre monitored the NVP-related reaction reports for change in number and severity.
View Full Article: HERE
Go through the Journal: http://www.enlivenarchive.org/pharmacovigilance-and-drug-safety-open-access
Contact Us: pharmacovigilance-drugsafety@enlivenarchive.org
